Azanta

Azanta is a specialty pharmaceutical company headquartered in Denmark, focused on the development and commercialization of niche medical products. The company's portfolio primarily addresses needs in women's health, oncology, and orphan drugs, with its flagship product, Angusta, being a widely recognized oral treatment for labor induction. Azanta also markets Nimoral, a hypoxic radiosensitizer used to enhance the efficacy of radiotherapy in head and neck cancer patients. In June 2020, the company was acquired by Norgine, integrating its specialized product line into Norgine's broader European commercial infrastructure. The acquisition allowed for the expanded distribution of Azanta's innovative therapies across international markets.